ArticleACS omega2026
A Novel Microfluidic System for Immunomagnetic Isolation of Pancreatic Cancer CTCs: Plectin‑1 and EpCAM as Potential Tumor Markers.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, with a five year survival rate below 10%. The high mortality rate of PDAC is primarily due to its aggressive metastatic nature, late diagnosis, and resistance to available therapies. A strategic research direction that demands significantly more attention is the identification of novel tumor markers and the development of tools for rapid, noninvasive diagnosis of this type of cancer. Circulating tumor cells (CTCs) are a promising target for early cancer detection via liquid biopsy, but their clinical application in PDAC is limited due to their rarity and technical challenges in reliable isolation and analysis. CTCs are typically isolated based on physical properties (size, density, deformability, charge, shape, hydrodynamics) or antigenic markers using specific antibodies. Although numerous cancer-specific antibodies have been identified, a marker uniquely distinguishing PDAC has yet to be found. In this work, we present the latest results concerning the development of a microfluidic platform that enables effective immunomagnetic isolation of PDAC cells from a complex biological sample using two potential PDAC markers: Plectin-1 and EpCAM. Here, we developed a low-cost, easy-to-manufacture, and user-friendly 3D-printed microfluidic platform that integrates a micromixer and a separation chamber for rapid cell isolation. Optimization tests showed that Plectin-1 at a concentration of 0.485 μg/mL captured 10
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.